PHOX-Type Chiral Ligands for Asymmetric Catalysis: Applications and Growth Prospects
How PHOX-type ligand libraries support catalyst screening, stereoselective route development and process-chemistry innovation.
Asymmetric catalysis can reduce step count and avoid resolution when a suitable catalyst system is found. Rlavie’s phosphino-oxazoline-containing chiral ligand offering gives medicinal and process chemists a practical set of structures for catalyst screening and route optimization.
How customers use the library
Published PHOX-family research evaluates ligands across enantioselective bond-forming reactions, hydrogenation and other transition-metal-catalyzed transformations. A structurally varied library helps teams compare steric and electronic effects quickly, identify promising lead catalysts and refine selectivity for a target substrate.
Market opportunity
The long-term driver is the pharmaceutical and fine-chemical sector’s need for efficient access to single-enantiomer products. Pressure to improve atom economy, reduce waste and shorten manufacturing routes strengthens the case for high-performance asymmetric catalysts. Suppliers that combine ligand breadth with dependable identity and analytical support are well positioned.
Rlavie support
Rlavie can support screening-set selection, individual ligand supply and discussions around custom analogues. Customers should match the ligand, metal precursor and reaction conditions experimentally; catalog availability is an enabling tool for development rather than a performance guarantee.
The listed Rlavie compound has a piperidine-based P,N-ligand architecture. Published results for other PHOX or NeoPHOX structures provide screening context, not validated performance data for this exact CAS. Selectivity, catalyst compatibility and stability require experiments with the chosen material.
Products to evaluate for your project
(2R)-2-[(4R)-4,5-Dihydro-4-(phenylmethyl)-2-oxazolyl]-1-(diphenylphosphino)piperidine (CAS 2757084-65-2).
Related Rlavie products
- (2R)-2-[(4R)-4,5-Dihydro-4-(phenylmethyl)-2-oxazolyl]-1-(diphenylphosphino)piperidine — CAS 2757084-65-2
Contact Rlavie for specifications and a quotation, or discuss custom synthesis.
Resources and references
- NeoPHOX: experimental study of a tunable phosphinooxazoline ligand system
- ICH Q11: pharmaceutical process development
- ICH Q14: analytical procedure development
Links and product identities reviewed on 16 September 2026. Application outlook is qualitative; availability, specifications and suitability are confirmed by project enquiry.